Search results
Results from the WOW.Com Content Network
An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]
Valproate is known to cause serious abnormalities or birth defects in the unborn child if taken during pregnancy, [7] [8] and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition and the person is also prescribed a contraceptive.
Guidelines on the choice of agents and how best to step up treatment for various subgroups in hypertension (high blood pressure) have changed over time and differ between countries. A Comparison of International Guidelines on Goal Blood Pressure and Initial Therapy for Adults With Hypertension (adapted from JNC 8 guidelines [ 1 ] )
Depakote (valproic acid/sodium valproate) – an antiepileptic and mood stabilizer used to treat bipolar disorder, neuropathic pain and others; sometimes called an antimanic medication. Depakene is the trade name for the same drug prepared without sodium. Desyrel – an atypical antidepressant used to treat depression and insomnia
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]
Conversion between extended-release and immediate-release (or "regular") morphine is easier than conversion to or from an equianalgesic dose of another opioid with different half-life, with less risk of altered pharmacodynamics.
Reversible dementia; Reversible cerebral atrophy; Abnormal behaviour [b]; Psychomotor hyperactivity [b]; Learning disorder [b]; Hyperammonaemia; Hypothyroidism; Bone marrow failure
The broad range of ligands that bind to the ER can create a spectrum of ER complexes that are fully estrogenic or antiestrogenic at a specific target site. [ 3 ] [ 4 ] [ 20 ] The main result of a ligand-binding to ER is a structural rearrangement of the ligand- binding pocket , primarily in the AF-2 of the C-terminal region.